欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
[目的]观察”固本解毒祛瘀”方药联合化疗治疗非小细胞肺癌（NSCLC）患者疗效观察.[方法]将80例非小细胞肺癌患者随机分为两组,对照组40例采用单纯化疗加对症治疗,治疗组40例在对照组基础上加用“固本解毒祛瘀”方药治疗,比较两组外周血常规、血T淋巴细胞亚群及卡氏（KPS）评分.[结果]与治疗前相比较,治疗组与对照组血WBC、HGB和PLT均减低（P〈0.05）,而对照组减低更明显（P〉0.05）;与治疗前比较,治疗组在CD3＋、CD4＋、CD4＋/CD8＋较治疗前明显上升,有显著差异（P〈0.01）,而对照组治疗后CD3＋水平下降,与治疗前比较,有显著性差异（P〈0.05）;KPS评分治疗组治疗前后组内比较,差异有统计学意义（P〈0.05）.[结论]“固本解毒祛瘀”方药可以减轻晚期NSCLC化疗患者骨髓抑制,增强免疫功能及改善生存质量.
英文摘要：
[Objective] To investigate the effect of Guben Jiedu Quyu prescription with chemotherapy on the non-small cell lung cancer （NSCLC）. [Methods ] Total of 80 NSCLC patients who received treatment were enrolled. The patients were divided into two groups based on the treatment. Forty patients in control group were received chemotherapy and forty patients in treatment group were received chemotherapy and Guben Jiedu Quyu prescription. The blood routine examination, peripheral blood Tlymphocyte subsets, and Karnofsky Performance Scores （KPS） were compared between two groups. [Results] The blood WBC,HGB and PLT were significantly decreased in the treatment group and the control group after treatment （P〈0.05）,While the control group was more significantly decreased than the treatment group （P〉0.05）. Forthe peripheral blood T lymphocyte subsets,the CD3＋、 CD4＋、 CD4＋/CD8＋were all increased in the treatment group （P〈0.01）,while the CD3＋ was decreased in the control group （P〈0.05）. The KPS was also improved in the experiment group （P〈0.05）. [Conclusion] Guben Jiedu Quyu prescription can reduce bone marrow suppression of chemotherapy,enhance immune function and improve the quality of life ofNSCLC patients.
同期刊论文项目
同项目期刊论文
期刊信息
位置：